Characteristic | Sample of trials with at least one SAE posted at ClinicalTrials.gov | Sample of trials with corresponding published article |
---|---|---|
(n = 300) | (n = 202) | |
Study phase | ||
III | 234 (78) | 168 (83) |
IV | 66 (22) | 34 (17) |
Study design | ||
Parallel groups | 287 (95) | 197 (97) |
Cross-over | 9 (3) | 5 (3) |
Factorial | 2 (1) | 0 (0) |
Other | 2 (1) | 0 (0) |
No. of intervention groups | ||
Two | 233 (78) | 169 (88) |
Three | 60 (20) | 33 (12) |
Other | 7 (2) | 0 (0) |
Primary funding source | ||
Industry | 264 (88) | 178 (88) |
US National Institutes of Health | 8 (3) | 7 (3) |
US federal funding | 1 (0) | 1 (1) |
Other | 27 (9) | 16 (8) |
Medical condition | ||
Endocrinology | 41 (14) | 32 (16) |
Infectious diseases | 38 (13) | 22 (11) |
Cardiology | 31 (10) | 18 (9) |
Neurology | 29 (10) | 23 (11) |
Oncology | 29 (10) | 23 (11) |
Rheumatology | 22 (7) | 13 (7) |
Pulmonary | 20 (6) | 15 (7) |
Other | 90 (30) | 56 (28) |
Study location | ||
At least one site in the United States | 205 (68) | 140 (69) |
No site in the United States | 95 (32) | 62 (31) |
Type of journal | ||
Specialty | 165 (82) | |
General | 37 (18) | |
ClinicalTrials.gov NCT reported in article | ||
Yes | 162 (80) | |
No | 40 (20) |